SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
NASDAQ:INDP

Indaptus Therapeutics - INDP Stock Forecast, Price & News

$2.10
-0.09 (-4.11%)
(As of 10/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.08
$2.27
50-Day Range
$2.10
$3.33
52-Week Range
$1.89
$8.17
Volume
43,261 shs
Average Volume
14,933 shs
Market Capitalization
$17.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Indaptus Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
638.1% Upside
$15.50 Price Target
Short Interest
Healthy
0.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$29,255 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.85) to ($2.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

144th out of 1,075 stocks

Pharmaceutical Preparations Industry

50th out of 537 stocks

About Indaptus Therapeutics

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Receive INDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INDP Stock News Headlines

Indaptus Therapeutics Inc
Indaptus Therapeutics GAAP EPS of -$0.41
Recap: Indaptus Therapeutics Q4 Earnings
Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I (INDP)
See More Headlines
Receive INDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INDP Company Calendar

Last Earnings
8/08/2022
Today
10/07/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INDP
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+638.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-7,710,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.38 per share

Miscellaneous

Free Float
5,286,000
Market Cap
$17.35 million
Optionable
Not Optionable
Beta
0.92

Key Executives

  • Mr. Jeffrey A. MecklerMr. Jeffrey A. Meckler (Age 55)
    CEO & Director
    Comp: $958.84k
  • Dr. Michael J. Newman Ph.D. (Age 66)
    Founder, Chief Scientific Officer & Director
    Comp: $468.82k
  • Mr. Walt Addison Linscott Esq. (Age 61)
    Chief Bus. Officer
    Comp: $719.13k
  • Mr. Nir Sassi (Age 46)
    CFO, Sec. & Treasurer
  • Dr. Boyan Vesselinov Litchev M.D. (Age 55)
    Chief Medical Officer













INDP Stock - Frequently Asked Questions

Should I buy or sell Indaptus Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indaptus Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INDP shares.
View INDP analyst ratings
or view top-rated stocks.

What is Indaptus Therapeutics' stock price forecast for 2022?

2 equities research analysts have issued 1 year target prices for Indaptus Therapeutics' stock. Their INDP share price forecasts range from $15.00 to $16.00. On average, they expect the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 638.1% from the stock's current price.
View analysts price targets for INDP
or view top-rated stocks among Wall Street analysts.

How have INDP shares performed in 2022?

Indaptus Therapeutics' stock was trading at $5.70 on January 1st, 2022. Since then, INDP stock has decreased by 63.2% and is now trading at $2.10.
View the best growth stocks for 2022 here
.

When is Indaptus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our INDP earnings forecast
.

How were Indaptus Therapeutics' earnings last quarter?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) issued its earnings results on Monday, August, 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.03.

What is Indaptus Therapeutics' stock symbol?

Indaptus Therapeutics trades on the NASDAQ under the ticker symbol "INDP."

How do I buy shares of Indaptus Therapeutics?

Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Indaptus Therapeutics' stock price today?

One share of INDP stock can currently be purchased for approximately $2.10.

How much money does Indaptus Therapeutics make?

Indaptus Therapeutics (NASDAQ:INDP) has a market capitalization of $17.35 million.

How can I contact Indaptus Therapeutics?

Indaptus Therapeutics' mailing address is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. The official website for the company is intecpharma.com. The company can be reached via phone at (646) 374-8050, via email at will.oconnor@sternir.com, or via fax at 972-2586-9176.

This page (NASDAQ:INDP) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.